Any current/future new fundraising through debt or equity?

No current or immediate plans for fundraising through debt or equity were mentioned. Rahul Batra stated that for reaching the target of Rs. 450-500 crores revenue, the company does not require any external funds. Planned CAPEX of Rs. 30-35 crores over the next 2 years will be funded entirely through internal cash accruals. Focus is on internal growth, business operations, and migrating to the Mainboard without involving fundraising activities. No discussions have been held regarding share split or issuing bonus shares to improve liquidity; the focus remains on business growth and Mainboard mig

Any current/future capex/capital investment/strategic investment?

Total planned CAPEX for the next 2 years: Rs. 30-35 crores, funded through internal cash accruals. Major CAPEX focus on setting up a cosmetology manufacturing plant by FY26 to expand SKUs from 14 to 40-50. Additional CAPEX expected for acquiring marketing authorizations (MAs) post-EU GMP audit to speed up product launches in regulated markets. No further oncology capacity expansion planned until sales reach Rs. 500 crores; investments will instead focus on MA acquisitions. Expansion includes increasing efforts in dermatology and cosmetology manufacturing facilities. CAPEX related to

Future growth expectations in sales/revenue/volumes?

Company expects a sales growth of 25%-30% for FY25, continuing previous growth trends. Oncology segment projected to grow to Rs. 450-500 crores within 2 years. Cosmetology/dermatology segment aims to reach Rs. 30-40 crores in revenue in next 3-5 years, starting from Rs. 1 crore sales in April FY24 and targeting Rs. 14-15 crores in FY24-25. Exports expected to increase significantly, targeting 35% of total business volume over next 2-3 years with focus on regulated markets like Colombia, Mexico, Brazil, and Southeast Asia. Company plans to increase number of SKUs in cosmetology from cur

Future growth expectations in earnings/operating earnings/profits/EPS?

Beta Drugs aims to sustain a sales growth rate of 25% to 30% for FY25 and beyond. The company plans to improve EBITDA margins to 24%-26% in FY24-25, after a decline due to high platins raw material costs and cosmetology division losses. Oncology segment EBITDA margin stands at 22.8%, excluding cosmetology losses, with a focus on boosting profitability by shifting focus from platins to other products. Cosmetology division, currently marginally profitable with Rs. 1 crore sales, targets Rs. 14-15 crore sales in FY24-25, with long-term brand-building potential. Exports are targeted to grow signif

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention specific figures or details about the current or expected order book or pending orders for Beta Drugs Limited. The management highlights ongoing efforts including 350+ dossiers filed for regulatory approvals, with business expected to flow in the next year. They mention participation in bulk purchase tenders (e.g., Tata Memorial Hospital), expecting to get a share of such orders, potentially benefiting the company. The company is focusing on product launches, including 6 new NDDS approvals expected between October and March, likely boosting future sal

Beta Drugs LtdQ4 FY24Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,849.7P/E: 45.0Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Company expects a sales growth of 25%-30% for FY25, continuing previous growth trends.
Oncology segment projected to grow to Rs. 450-500 crores within 2 years.
Cosmetology/dermatology segment aims to reach Rs. 30-40 crores in revenue in next 3-5 years, starting from Rs. 1 crore sales in April FY24 and targeting Rs. 14-15 crores in FY24-25.
Exports expected to increase significantly, targeting 35% of total business volume over next 2-3 years with focus on regulated markets like Colombia, Mexico, Brazil, and Southeast Asia.
Company plans to increase number of SKUs in cosmetology from current 14 to 40-50 by FY25.
CAPEX of Rs. 30-35 crores planned over next 2 years (internal accrual-funded) mainly for cosmetology plant (to start FY26) and acquiring marketing authorizations post EU GMP audit.
Overall strategy focuses on brand creation, sales, profitability, and migration to Mainboard within 2 months to improve visibility and liquidity.

Margin guidance

Category 3

Beta Drugs aims to sustain a sales growth rate of 25% to 30% for FY25 and beyond.
The company plans to improve EBITDA margins to 24%-26% in FY24-25, after a decline due to high platins raw material costs and cosmetology division losses.
Oncology segment EBITDA margin stands at 22.8%, excluding cosmetology losses, with a focus on boosting profitability by shifting focus from platins to other products.
Cosmetology division, currently marginally profitable with Rs. 1 crore sales, targets Rs. 14-15 crore sales in FY24-25, with long-term brand-building potential.
Exports are targeted to grow significantly, expected to contribute around 35% of total revenue in future years with higher margins in regulated markets.
Management assures delivering consistent growth and profitability over the next 3-5 years with a focus on innovative oncology products and expanding dermatology and cosmetology offerings.

See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No current or immediate plans for fundraising through debt or equity were mentioned.
Rahul Batra stated that for reaching the target of Rs. 450-500 crores revenue, the company does not require any external funds.
Planned CAPEX of Rs. 30-35 crores over the next 2 years will be funded entirely through internal cash accruals.
Focus is on internal growth, business operations, and migrating to the Mainboard without involving fundraising activities.
No discussions have been held regarding share split or issuing bonus shares to improve liquidity; the focus remains on business growth and Mainboard migration.

Order book

The transcript does not explicitly mention specific figures or details about the current or expected order book or pending orders for Beta Drugs Limited.
The management highlights ongoing efforts including 350+ dossiers filed for regulatory approvals, with business expected to flow in the next year.
They mention participation in bulk purchase tenders (e.g., Tata Memorial Hospital), expecting to get a share of such orders, potentially benefiting the company.
The company is focusing on product launches, including 6 new NDDS approvals expected between October and March, likely boosting future sales.
The management projects 25%-30% sales growth for FY25, indicating a positive outlook on order inflows.
No direct or explicit data on the order book size or pending orders is provided in the available transcript.

See what Beta Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Total planned CAPEX for the next 2 years: Rs. 30-35 crores, funded through internal cash accruals.
Major CAPEX focus on setting up a cosmetology manufacturing plant by FY26 to expand SKUs from 14 to 40-50.
Additional CAPEX expected for acquiring marketing authorizations (MAs) post-EU GMP audit to speed up product launches in regulated markets.
No further oncology capacity expansion planned until sales reach Rs. 500 crores; investments will instead focus on MA acquisitions.
Expansion includes increasing efforts in dermatology and cosmetology manufacturing facilities.
CAPEX related to asset purchase mainly involves marketing authorizations for faster market entry rather than machinery.
Current cosmetology CAPEX estimated around Rs. 30-35 crores.

Track Beta Drugs Ltd — get its next earnings analysis in your feed

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBeta Drugs Ltd

Rev 2Mar 3

See where Beta Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →